These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8549396)

  • 1. Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Watanabe K; Yoshida M; Ishibashi T; Yamada H; Kido M; Hirose T; Maeda F; Matsuzaki Y
    Drugs; 1995; 49 Suppl 2():448-50. PubMed ID: 8549396
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
    Kawahara S; Watanabe Y; Matsuka Y; Sato T; Takahashi K
    Drugs; 1995; 49 Suppl 2():414-5. PubMed ID: 8549382
    [No Abstract]   [Full Text] [Related]  

  • 3. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections.
    Sawae Y; Ninomiya K; Takaki K; Shimono N; Misumi H; Okada K
    Drugs; 1995; 49 Suppl 2():430-2. PubMed ID: 8549390
    [No Abstract]   [Full Text] [Related]  

  • 5. Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.
    Sufarlan AW; Zainudin BM; Pit S; Ishak I
    Drugs; 1995; 49 Suppl 2():442-5. PubMed ID: 8549394
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 8. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 9. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment in general practice. Effective, well tolerated therapy].
    MMW Fortschr Med; 2000 Sep; 142(37):58-9. PubMed ID: 11026226
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of ofloxacin in lower respiratory tract infections bacteriologically diagnosed by fibreoptic-bronchoscopy aspirate culture.
    Tomasic-Cvitanovic S; Kotaraki Z
    Drugs; 1995; 49 Suppl 2():446-7. PubMed ID: 8549395
    [No Abstract]   [Full Text] [Related]  

  • 12. An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
    Harazim H; Wimmer J; Mittermayer HP
    Drugs; 1987; 34 Suppl 1():71-3. PubMed ID: 3481331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
    Sato A; Ogawa H; Iwata M; Ono T; Yasuda K; Nagayama M; Shirai T; Shirai M; Ida M; Suda T
    Drugs; 1995; 49 Suppl 2():428-9. PubMed ID: 8549388
    [No Abstract]   [Full Text] [Related]  

  • 14. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 15. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of quinolones in respiratory tract infections.
    Maesen FP; Davies BI; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections.
    Bariffi F; Giacomelli P; Sanduzzi A; Perna F; De Masi AL
    Int J Clin Pharmacol Res; 1987; 7(3):199-201. PubMed ID: 3474212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ofloxacin in lower respiratory tract infections.
    Hänninen P
    Drugs; 1987; 34 Suppl 1():179-80. PubMed ID: 3481320
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?].
    Roig J; Martínez Benazet J; Casal J
    Arch Bronconeumol; 2002 Nov; 38(11):547; author reply 547-8. PubMed ID: 12435323
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.